Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
VEGFD/VEGFR2 axis induces the dedifferentiation of high endothelial venules and impairs lymphocyte homing
Weichang Yang, Juan Wu, Shanshan Cai, Hongquan Xing, Jiajia Xiang, Xinyi Zhang, Xiaoyan Su, Xiaoqun Ye
Weichang Yang, Juan Wu, Shanshan Cai, Hongquan Xing, Jiajia Xiang, Xinyi Zhang, Xiaoyan Su, Xiaoqun Ye
View: Text | PDF
Research Article Immunology Pulmonology

VEGFD/VEGFR2 axis induces the dedifferentiation of high endothelial venules and impairs lymphocyte homing

  • Text
  • PDF
Abstract

High endothelial venules (HEVs) are important structures in lymph nodes (LNs) that mediate lymphocyte homing, and their dedifferentiation is a necessary step before LN metastasis. Whether vascular endothelial growth factor–related (VEGF-related) signaling, which plays an important role in LN metastasis, is involved in the dedifferentiation of HEVs remains unclear. Here, we confirmed increased expression of VEGFA, VEGFC, and VEGFD; HEV dedifferentiation; and impaired lymphocyte homing function in tumor-draining LNs (TDLNs). Furthermore, we demonstrated that tumor-secreted VEGFA induced lymphangiogenesis in TDLNs to promote premetastatic niche (PMN) formation; VEGFC promoted HEV proliferation but did not affect its lymphocyte homing function. Notably, we showed that VEGFD induced the dedifferentiation of HEVs by binding to VEGFR2 on the endothelial surface of HEVs and further impaired the lymphocyte homing function of TDLNs. Overall, we revealed that tumor-secreted VEGFD interacted with VEGFR2, induced HEV dedifferentiation, and reduced lymphocyte homing, providing potential insights for the prevention and treatment of LN metastasis.

Authors

Weichang Yang, Juan Wu, Shanshan Cai, Hongquan Xing, Jiajia Xiang, Xinyi Zhang, Xiaoyan Su, Xiaoqun Ye

×

Figure 8

VEGFD/VEGFR2 axis regulates lymphocyte homing of HEV.

Options: View larger image (or click on image) Download as PowerPoint
VEGFD/VEGFR2 axis regulates lymphocyte homing of HEV.
(A) The percentage...
(A) The percentage of CD4+ and CD8+ T cells and DCs in tumor draining lymph node (TDLN) between control, VEGFD-OE, and DC101 groups by flow cytometry (FCM) (n = 4). (B) The percentage of CFSE+ cells in TDLN by FCM (C) (n = 4). (C) Immunohistofluorescence staining for CD4 (pink) and MECA-79 (green) in each group (n = 4). (D) FCM of LTβR expression on the surface of high endothelial venule (HEV) in TDLN between 3 groups (n = 4). (E) FCM of Tregs in control and VEGFD-OE groups (n = 4). (F) FCM of CD4+CCR7+ in control and VEGFD-OE groups (n = 4). (G) FCM of CD8+CD69+ in control and VEGFD-OE groups (n = 4). (H) FCM of CD8+PD1+ in control and VEGFD-OE groups (n = 4). (I) IHC of CCL19 expression in each group (n = 4). (J) IHC of CCL21 expression in each group (n = 4). In this figure, data are shown as mean ± SD. (A–D, I, and J) P value measured by 1-way ANOVA with Dunnett’s multiple-comparison test. (E–H) P values were measured by unpaired, 2-tailed Student’s t test with or without Welch’s correction analysis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Scale bars: 20 μm (C) and 50 μm (I and J).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts